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Matt Schipper1, Paul Stanton1, Jinming Yu2 and Feng-Ming Spring Kong1,6,7*Abstract
Purpose: To study whether esophageal FDG activity changes by time of mid-course of fractionated radiotherapy
(RT), and whether these changes are associated with radiation esophagitis in patients with non-small cell lung
cancer (NSCLC).
Methods: Fifty patients with stage I-III NSCLC were enrolled prospectively and, all received ≥60 Gy RT. FDG-PET/CT
scans were acquired prior to, and during-RT after delivery of 45 Gy. Normalized standardized uptake values (NSUV),
defined by the esophageal maximum SUV relative to intravascular background level in the aortic arch, were sampled in
the esophagus at the level of the primary tumor, sternal notch, aortic arch, carina, and gastro-esophageal junction.
Symptomatic radiation esophagitis was defined as an event.
Results: Compared to baseline, esophageal NSUV increased significantly during-RT at the level of the primary
tumor (1.09 ± 0.05 vs.1.28 ± 0.06, p = 0.001), but did not change at other levels in the esophagus. 16 patients had
radiation esophagitis events and these patients had significantly higher during-RT to baseline NSUV ratios than
those without esophagitis (1.46 ± 0.12, 95% CI 1.20-1.71; vs. 1.11 ± 0.05, 95% CI 1.01-1.21, p = 0.002). Maximum
esophageal dose (p = 0.029), concurrent chemotherapy (p = 0.022) and esophageal FDG PET NSUV ratio (during-RT
to baseline, p = 0.007), were independent factors associated with esophagitis and area under curves (AUC) were
0.76, 0.70 and 0.78, respectively. Combining esophageal maximum dose and FDG PET NSUV Ratio at the tumor
level increased AUC to 0.85 (p = 0.016).
Conclusion: FDG uptake increased in esophagus during-RT and this increase may predict radiation esphagitis
during later course of treatment.
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Esophagitis is a common complication of patients who
undergo thoracic radiation therapy (RT) for non–small
cell lung cancer (NSCLC) and a source of considerable
morbidity [1,2]. Patients often complain of dysphagia and/
or odynophagia late during the course of fractioned radio-
therapy. Severe esophagitis can necessitate hospitalization,
initiation of percutaneous or parenteral feeding, and* Correspondence: fengkong@gru.edu
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reproduction in any medium, provided the ortreatment interruption. These complications signifi-
cantly affect quality of life and can negatively impact
long-term survival [3].
Clinical and dosimetric studies predicting the risk of
radiation esophagitis have been performed [4-6]. For ex-
ample, concurrent chemotherapy and esophageal radiation
dose were correlated with the clinical severity of esopha-
gitis, in some reports [7,8]. 18Fluorodeoxyglucose-positron
emission tomography (FDG-PET) can show the functional
status of a tumor through the visualization of its meta-
bolic activity gauged by FDG uptake, and it can also
provide additional information to aid in the understand-
ing of radiation induced-esophagitis. Some investigatorsd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Esophageal uptakes of FDG were measured at tumor
level and other levels marked.
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therapy [9-14]. However, the correlation of esophageal
FDG uptake and clinical signs and symptoms of radi-
ation induced-esophagitis were not well studied. The
purpose of this study was to examine whether esopha-
geal FDG activity changes by mid-course of fractionated
RT, and whether these changes in esophageal FDG up-
take are associated with radiation induced-esophagitis
late during course of treatment in patients with NSCLC.
Materials and methods
Study population
The study population included consecutively enrolled
patients in prospective studies of FDG PET to predict
treatment outcomes, approved by the institutional review
board of University of Michigan. Adult patients with histo-
logically confirmed stage I to III NSCLC (AJCC 2003)
undergoing definitive radiation with or without chemo-
therapy were enrolled in the study. Patients with small
cell lung cancer or mixed small cell/non-small cell tumor
histology, pericardial effusion, pregnant or lactating were
excluded from the study. This study received ethical ap-
proval from the institution review boards of University of
Michigan and Ann Arbor VA. Written informed consent
was obtained from the patient for publication of this Case
report and any accompanying images. A copy of the writ-
ten consent is available for review by the Editor-in-Chief
of this journal.
FDG PET/CT imaging
The FDG-PET/CT scans were acquired 1–2 weeks be-
fore RT (pre-RT), and after the delivery of approximately
45 Gy (during-RT). The time of delivery of approxi-
mately 45 Gy of the total prescribed dose was chosen for
the during-RT scan, with the intent that a dose to this
threshold would provide control of microscopic disease
and leave a reasonable amount of treatment remaining
to alter the radiation therapy plan to include an add-
itional RT boost. In cases of radiation administered in
fractions other than 2 Gy, tumor dose was converted to
a biological equivalent dose of approximately 45 Gy in
2-Gy fractions.
The FDG-PET/CT scans were performed using a hybrid
PET/CT scanner (Biograph Classic; Siemens Medical
Solutions, Hoffman Estates, IL), with arms raised above
the head in treatment position, as previously described
[15]. Blood glucose levels were screened prior to PET
and were less than 150 mg/ml. CT images (5-mm slices)
for the PET/CT study were obtained during quiet venti-
lation. Emission PET images were obtained beginning
60 minutes after administration of 8 to 10 mCi of [18 F]
FDG. PET scans were evaluated qualitatively by both a
nuclear medicine physician (R.B.) and a radiation on-
cologist (S. Y.), and by objective quantification of FDGuptake in regions of interest (ROI). SUV estimation was
performed using e.soft express (version 3.5; Siemens
Medical Solutions). SUVmax activity, relative to intravas-
cular background from the aortic arch, was measured in
the esophagus at the level of the lung tumor level, the ster-
nal notch, aortic arch, carina, gastric-esophageal junction
and other normal tissues including axillary fat, liver, and
erector muscle of spine (Figure 1). Given that SUV varies
with many factors, such as the exact amount of radioactive
tracer administrated, the interval between tracer injec-
tion and the scanning time, the blood glucose level, etc.,
normalized SUV was used (NSUV) to measure the FDG
activity of each region of interest (ROI) to improve re-
producibility. NSUV was calculated as: f: NSUV = SUV
max of ROI/ mean SUV of the aortic arch [15]. SUV-
max was chosen to measure the esophagus because it is
the most reproducible measurement and a commonly
used clinical parameter. Mean SUV is more representa-
tive of the activity of mediastinal background in the aor-
tic arch where FDG uptake is more homogeneous and
this is a standard area to determine background blood
pool FDG activity.Esophagitis
Radiation-induced esophagitis, represented clinically by
the presence of either dysphagia or odynophagia, was
assessed weekly and graded prospectively according to
the National Cancer Institution (NCI) Common Toxicity
Criteria for Adverse Events (CTCAE), version 3.0. The
maximum degree of esophagitis documented during
Table 1 Patient characteristics and symptomatic esophagitis







Male 41 27 14
Female 9 7 2
Median Age 68 71 65 0.044 >0.05
(95% CI) (61–75) (68–73) (60–71)
Clinical stage 0.032 >0.05
I 14 12 2
II 9 8 1
III 27 14 13
Histology 0.163
Adenocarcinoma 6 3 3
Squamous carcinoma 11 10 1
NSCLC, unspecified 33 21 12
Concurrent chemotherapy 0.004 0.022
With 33 18 15
Without 17 16 1
Mean tumor dose 68.0 66.2 66.2 0.380
(95% CI, Gy) (65.0–71.3) (63.6–68.9) (65.3–70.9)
Maximal esophageal dose 55.1 47.9 69.0 0.001 0.029
(95% CI, Gy) (48.5–61.6) (39.0–56.8) (65.5–72.4)
Esophagus FDG uptake change at tumour level (During-RT/pre-RT) 1.22 1.11 1.46 0.002 0.007
(1.11–1.33) (1.01–1.21) (1.20–1.71)
Abbreviations: CI confidence interval, UV univariate analysis, MV multivariate analysis.
Table 2 Changes of relative FDG uptake during the
course of radiotherapy
FDG uptake (NSUV) Pre-RT During-RT P
Mean 95% CI Mean 95% CI
Esophagus
Sternal notch level 1.03 0.94–1.17 1.07 0.96–1.18 0.572
Aortic arch level 1.03 0.96–1.13 1.11 1.01–1.22 0.139
Carina level 1.17 1.05–1.28 1.25 1.12–1.37 0.244
Pulmonary ligament level 1.16 1.04–1.27 1.28 1.15–1.41 0.168
GE junction 1.27 1.12–1.39 1.39 1.24–1.56 0.189
Tumour level 1.09 1.00–1.18 1.28 1.17–1.39 0.001
Axillary fat 0.24 0.21–0.26 0.25 0.21–0.28 0.429
Liver 1.43 1.34–1.49 1.33 1.20–1.46 0.157
Erector muscle of spine 0.51 0.37–0.60 0.43 0.36–0.50 0.217
Abbreviation: NSUV normalized standard uptake value. All the FDG uptake was
normalized to that of aortic arch.
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the study endpoint for each patient.
Statistical consideration
The differences in FDG activity between time points were
assessed by paired t-test and the difference between pa-
tients with and without symptomatic radiation esophagitis
was assessed by independent t-test. A binary Logistic re-
gression analysis model was used to test the correlations
between symptomatic radiation-induced esophagitis, FDG
activity ratio change and clinical findings. The perform-
ance of predictive models for esophagitis was analyzed by
area under receiver operating characteristic curve (AUC).
Results
Patient characteristics and their relationship with
radiation esophagitis
A total of 50 patients with stage I-III NSCLC requiring
radiation therapy were enrolled from 2003 to 2009.
Minimum follow-up was 24 months for surviving patients.
All patients had FDG PET/CT scans within 1–2 weeks
prior to the initiation of radiation therapy and after delivery
of approximately 45 Gy (during-RT). Patient demographics
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medically inoperable stage I–II disease and the remaining
27 (54%) patients had locally advanced stage IIIA–B dis-
ease. Thirty-three patients (66%) received concurrent
chemo-radiotherapy, while the remaining patients received
definitive radiation alone. The average mean radiation dose
to tumor was 68.0 (95% CI 65.0-71.3) Gy while the average
mean and maximum radiation dose to the esophagus was
22.1 (95% CI 17.9-26.3) and 55.1 (95% CI 48.5-61.6) Gy,
respectively.
Sixteen of 50 (32%) patients had clinically apparent
radiation-induced esophagitis. These patients were younger
than patients without symptomatic esophagitis (Median
age 65 vs. 71, p = 0.044). Patients with stage III NSCLC
had a higher rate of radiation-induced esophagitis than
those with stage I-II (48% vs. 13%, p = 0.032). Patients
treated with concurrent chemotherapy had a higher rateFigure 2 FDG-PET scans in a patient with symptomatic esophagitis. T
completion of radiotheapy.of esophagitis than those not treated with concurrent
chemotherapy (45% vs. 6%, p = 0.004). Patients with
esophagitis also had higher maximum esophageal radi-
ation dose (69.0 Gy vs. 47.9 Gy, p = 0.001) than patients
without esophagitis (Table 1). There were no differences
in gender, KPS, histology type and prescribed PTV dose
between patients with or without esophagitis.FDG-uptake and esophagitis
NSUV of esophagus pre-RT and during-RT FDG PET are
summarized in Table 2. No significant NSUV change
between pre-RT scan and during-RT scan was observed
in auxiliary fat (0.24 vs. 0.25, p = 0.429), liver (1.43 vs. 1.33,
p = 0.157) and prespinal muscle (0.51 vs. 0.43, p = 0.217).
Compared to baseline, esophageal NSUV increased signifi-
cantly during-RT at the level of the tumor (1.09 ± 0.05 vs.his patient received 66 Gy and required G-tube in 1 month after
Figure 3 FDG-PET scans in patient without symptomatic esophagitis.
Figure 4 Receiver operating characteristic (ROC)
curve comparision.
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elsewhere (Figures 2 and 3).
Patients with esophagitis had a significantly higher
during-RT to baseline NSUV ratio at the tumor level than
those without (1.46 [95% CI 1.20-1.71] vs. 1.11 [95% CI
1.01-1.21], p = 0.002).
Multivariate analysis for esophagitis
All significant univariate analysis factors were entered
into multivariate logistic regression analysis. Maximum
esophageal dose (p = 0.029), concurrent chemotherapy
(p = 0.022) and esophageal FDG PET NSUV (during-RT to
baseline, p = 0.007), were independent factors associated
with esophagitis (Table 1) with AUCs of 0.76, 0.70 and
0.78, respectively, under receiver operating characteristic
(ROC) curve analysis. Combining esophageal maximum
dose and FDG PET NSUV ratio at the tumor level in-
creased AUC to 0.85 (p = 0.016, Figure 4).
Discussion
We analyzed the FDG PET scans of 50 patients with
NSCLC and found that esophageal NSUV at the tumor
level increased during-RT. NSUV increase from pre-RT
is an independent measurement related to radiation-
induced esophagitis, reflecting the accumulation of FDG
in affected esophageal mucosa. Thus, FDG PET SUV may
be an important supplement to traditional dose volume
parameters associated with radiation-induced esophagitis.
Although there have been reports on the relationship
of radiation esophagitis and FDG-PET, to our know-
ledge, this is the first study documenting the correlation
between during-RT esophageal FDG-uptake and the pres-
ence of clinically documented radiation-induced esopha-
gitis [9-14]. This is in addition to reports of patients with
FDG uptake from bacterial esophagitis, Barrett’sesophagus or gastroesophageal reflux [16]. These condi-
tions are characterized by linear intense FDG uptake
throughout the esophagus not related to concurrent radio-
therapy. The majority of radiation esophagitis reports
using FDG PET are from esophageal cancer treatment
[17,18]. Bhargava et al. demonstrated increased esophageal
FDG activity that can be attributed to radiation therapy as
radiation esophagitis in a patient with NSCLC. This diag-
nosis was based on post-RT FDG PET imaging and
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kamp et al. demonstrated that esophageal FDG uptake
around 3 months after concurrent chemo-radiotherapy
was associated with grade of esophagitis, and that there
was a local dose–effect relationship with post-treatment
FDG uptake, in which dose levels >55 Gy were indicative
of increased FDG uptake [19]. However, a common factor
of all of these prior studies is their usage of post-RT FDG
PET. Our study of FDG-uptake during-RT provides the
opportunity to detect the radiation esophagitis objectively
on PET scan during-RT, which may predict radiation
esophagitis in the clinic. Furthermore, during-RT assess-
ments may guide radiation planning in each individual pa-
tient to esophagus sparing adaptive radiation therapy late
during course. Patients with intense FDG-uptake in
esophagus during-RT are at high risk for radiation
esophagitis and further radiation to esophagus should
be minimized in late course radiotherapy.
FDG activity may be used to supplement traditional
dose volume parameters associated with radiation-induced
esophagitis. In this study, we found that esophageal FDG
SUV increase, concurrent chemotherapy and maximal ra-
diation dose to the esophagus were independent factors
associated with the development of radiation esophagitis.
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